333 related articles for article (PubMed ID: 24283110)
1. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
Kaya A; Kurt M; Tanboğa IH; Işik T; Ekinci M; Aksakal E; Kaya Y; Topçu S; Sevimli S
Acta Cardiol; 2013 Oct; 68(5):489-94. PubMed ID: 24283110
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention.
Liu Y; Liu YH; Tan N; Chen JY; Zhou YL; Li LW; Duan CY; Chen PY; Luo JF; Li HL; Wei-Guo
PLoS One; 2014; 9(10):e111124. PubMed ID: 25357250
[TBL] [Abstract][Full Text] [Related]
3. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
[TBL] [Abstract][Full Text] [Related]
4. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: Results from the PRATO-ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome).
Leoncini M; Toso A; Maioli M; Tropeano F; Villani S; Bellandi F
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):71-9. PubMed ID: 24076283
[TBL] [Abstract][Full Text] [Related]
5. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
Sardella G; Lucisano L; Mancone M; Conti G; Calcagno S; Stio RE; Pennacchi M; Biondi-Zoccai G; Canali E; Fedele F
Int J Cardiol; 2013 Oct; 168(4):3715-20. PubMed ID: 23849964
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention.
Li W; Fu X; Wang Y; Li X; Yang Z; Wang X; Geng W; Gu X; Hao G; Jiang Y; Fan W; Wu W; Li S
Cardiology; 2012; 122(3):195-202. PubMed ID: 22854323
[TBL] [Abstract][Full Text] [Related]
7. Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea.
Kim MJ; Jeon DS; Gwon HC; Kim SJ; Chang K; Kim HS; Tahk SJ;
Clin Cardiol; 2012 Nov; 35(11):700-6. PubMed ID: 22825844
[TBL] [Abstract][Full Text] [Related]
8. Relationship between inflammation and benefits of early high-dose rosuvastatin on contrast-induced nephropathy in patients with acute coronary syndrome: the pathophysiological link in the PRATO-ACS study (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention).
Toso A; Leoncini M; Maioli M; Tropeano F; Di Vincenzo E; Villani S; Bellandi F
JACC Cardiovasc Interv; 2014 Dec; 7(12):1421-9. PubMed ID: 25523533
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
Kim JS; Kim J; Choi D; Lee CJ; Lee SH; Ko YG; Hong MK; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Lee NH; Cho YH; Cho DK; Jang Y
JACC Cardiovasc Interv; 2010 Mar; 3(3):332-9. PubMed ID: 20298994
[TBL] [Abstract][Full Text] [Related]
10. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Han Y; Zhu G; Han L; Hou F; Huang W; Liu H; Gan J; Jiang T; Li X; Wang W; Ding S; Jia S; Shen W; Wang D; Sun L; Qiu J; Wang X; Li Y; Deng J; Li J; Xu K; Xu B; Mehran R; Huo Y
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):62-70. PubMed ID: 24076297
[TBL] [Abstract][Full Text] [Related]
11. Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
Toso A; Leoncini M; Maioli M; Gallopin M; Tedeschi D; Amato M; Bellandi F
J Cardiovasc Med (Hagerstown); 2011 May; 12(5):318-21. PubMed ID: 21045713
[TBL] [Abstract][Full Text] [Related]
12. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Andò G; Morabito G; de Gregorio C; Trio O; Saporito F; Oreto G
Catheter Cardiovasc Interv; 2013 Nov; 82(6):878-85. PubMed ID: 23703775
[TBL] [Abstract][Full Text] [Related]
13. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the preventive efficacy of rosuvastatin versus atorvastatin in post-contrast acute kidney injury in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Dai Y; Huang J; Zeng L; Huang Z; Duan C; Shao S; Chen H; Xue L; Chen J; Tan N; He P; Liu Y; Yu D
Biomed Pharmacother; 2020 Aug; 128():110336. PubMed ID: 32521452
[TBL] [Abstract][Full Text] [Related]
15. Predictive Value of Gamma-Glutamyl Transferase Levels for Contrast-Induced Nephropathy in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Coronary Intervention.
Oksuz F; Yarlioglues M; Cay S; Celik IE; Mendi MA; Kurtul A; Cankurt T; Kuyumcu S; Canpolat U; Turak O
Am J Cardiol; 2015 Sep; 116(5):711-6. PubMed ID: 26116992
[TBL] [Abstract][Full Text] [Related]
16. Contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment.
Pyxaras SA; Sinagra G; Mangiacapra F; Perkan A; Di Serafino L; Vitrella G; Rakar S; De Vroey F; Santangelo S; Salvi A; Toth G; Bartunek J; De Bruyne B; Wijns W; Barbato E
Am J Cardiol; 2013 Mar; 111(5):684-8. PubMed ID: 23261003
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials.
Liang M; Yang S; Fu N
Medicine (Baltimore); 2017 Jul; 96(27):e7384. PubMed ID: 28682890
[TBL] [Abstract][Full Text] [Related]
18. Impact of high loading dose of atorvastatin in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention: a randomized controlled trial.
Shehata M; Hamza M
Cardiovasc Ther; 2015 Apr; 33(2):35-41. PubMed ID: 25677920
[TBL] [Abstract][Full Text] [Related]
19. Comparison of rosuvastatin versus atorvastatin for preventing postoperative atrial fibrillation.
Abaci O; Kocas C; Oktay V; Yildiz CE; Kilickesmez KO; Coskun U; Yildiz A; Yigit Z
Heart Surg Forum; 2013 Jun; 16(3):E158-61. PubMed ID: 23803242
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial.
Sardella G; Conti G; Donahue M; Mancone M; Canali E; De Carlo C; Di Roma A; Calcagno S; Lucisano L; Fedele F
Catheter Cardiovasc Interv; 2013 Jan; 81(1):E36-43. PubMed ID: 22517610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
